A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis

Romulus Scorei, Paul Mitrut, Iulian Petrisor, Iulia Scorei, Romulus Scorei, Paul Mitrut, Iulian Petrisor, Iulia Scorei

Abstract

The objective of this pilot study was to determine whether 15 days of dietary supplementation with calcium fructoborate could acutely modulate inflammatory and lipid blood markers in individuals diagnosed with primary osteoarthritis. During 2 weeks, a placebo-controlled, randomized, double-blind study was conducted on 116 subjects that were initially recruited. Seventy-two subjects started the study, being divided into four groups, and only 60 completed the study as designed. The aim was to compare the effects of calcium fructoborate to placebo on subjects diagnosed with knee primary osteoarthritis. The obtained outcomes were inflammation biomarkers (C-reactive protein, fibrinogen, and erythrocyte sedimentation rate) and lipid markers (triglycerides, total cholesterol, LDL cholesterol, and HDL cholesterol). No serious adverse events were reported. The calcium fructoborate showed beneficial effect on the inflammatory markers for all groups subjected to the treatment when compared with the placebo group and slight changes in the lipid metabolism. This study suggests that short-term (2 weeks) calcium fructoborate supplementation in patients with osteoarthritis symptoms has a favorable prognosis on inflammation diseases.

Figures

Fig. 1
Fig. 1
Flow chart for patient recruitment

References

    1. Newnham RE. Arthritis or skeletal fluorosis and boron. Int Clin Nutr Rev. 1991;11:68–70.
    1. Newnham RE. Essentiality of boron for healthy bones and joints. Environ Health Prospect. 1994;102(7):83–85. doi: 10.1289/ehp.94102s783.
    1. Korkmaz M, Sayl U, Sayl BS, Bakirdere S, Titretir S, Yavuz Ataman O, Keskin S. Estimation of human daily boron exposure in a boron-rich area. Brit J Nutr. 2007;98:571–575. doi: 10.1017/S000711450770911X.
    1. Helliwell TR, Kelly SA, Walsh HP, Klenerman L, Haines J, Clark R, Roberts NB. Elemental analysis of femoral bone from patients with fractured neck of femur or osteoarthritis. Bone. 1996;18:151–157. doi: 10.1016/8756-3282(95)00440-8.
    1. Newnham RE. Boron problems and its essential nature. In: Chazot G, Abdulla M, Arnaud P, editors. Current trends in trace elements research. Nishimura: Smith-Gordon; 1989. pp. 89–91.
    1. Travers RL, Rennie GC, Newnham RE. Boron and arthritis: the results of a double-blind pilot study. J Nutr Med. 1990;1:127–132. doi: 10.3109/13590849009003147.
    1. Hunt CD, Idso JP. Dietary boron as a physiological regulator of the normal inflammatory response: a review and current research progress. J Trace Elem Exp Med. 1999;12:221–233. doi: 10.1002/(SICI)1520-670X(1999)12:3<221::AID-JTRA6>;2-X.
    1. Hunt CD (2002) Dietary boron is a physiological regulator of the normal inflammatory response. In: Trace elements in man and animals, part 5. Springer, New York. pp 1071–1076, doi:10.1007/0-306-47466-2_327
    1. Nielsen FH. Biochemical and physiologic consequences of boron deprivation in humans. Environ Health Prospect. 1994;102:59–63.
    1. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care. 2002;8(suppl):S428–S430.
    1. Davies-Tuck M, Hanna F, Davis SR, Bell JR, Davison SL, Wluka AE, Adams J, Cicuttini FM. Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women—a prospective cohort study. Arthritis Res Ther. 2009;11:R181. doi: 10.1186/ar2873.
    1. Kadam UT, Jordan K, Croft PR. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales. Ann Rheu Dis. 2004;63:408–414. doi: 10.1136/ard.2003.007526.
    1. Persell SD, Lloyd-Jones DM, Baker DW. National Cholesterol Education Program risk assessment and potential for risk misclassification. Prev Med. 2006;43:368–371. doi: 10.1016/j.ypmed.2006.06.017.
    1. Van Leeuwen MA. Acute phase proteins in the monitoring of inflammatory disorders. Baillières Clin Rheumatol. 1994;8(3):531–552. doi: 10.1016/S0950-3579(05)80114-1.
    1. Sipe JD. Acute-phase proteins in osteoarthritis. Semin Arthritis Rheum. 1995;25(2):75–86. doi: 10.1016/S0049-0172(95)80020-4.
    1. Wolfe F, Goldberg R. The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. J Rheumatol. 1997;24:1486.
    1. Conrozier T, Chappuis-Cellier C, Richard M, Mathieu P, Richard S, Vignon E. Increased serum C-reactive protein levels by immunonephelometry in patients with rapidly destructive hip osteoarthritis. Rev Rhum Engl Ed. 1998;65(12):759–765.
    1. Dati F, Metzmann E (2005) Acute phase proteins. In: Proteins laboratory testing and clinical use. Media Print Taunusdruck GmbH, Frankfurt am Main. pp 52–53
    1. Fischbach F (2004) Immunodiagnostics studies. In: A manual of laboratory and diagnostics tests, 7th edn. Williams & Wilkins, Baltimore. pp 604–605
    1. Tarik M, Husain MD, Kim DH. C-reactive protein and erythrocyte sedimentation rate orthopedics. U P O J. 2002;15:13–16.
    1. Dessein PH, Stanwix AE. Inflammatory arthritis and cardiovascular disease may share a common predisposition. Rheumatology. 2001;40:703–704. doi: 10.1093/rheumatology/40.6.703.
    1. Dessein PH, Stanwix AE, Joffe BJ. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002;4:R5. doi: 10.1186/ar428.
    1. Miljkovic D, Scorei IR, Cimpoiasu VM, Scorei ID. Calcium fructoborate: plant-based dietary boron for human nutrition. J Diet Suppl. 2009;6:211–226. doi: 10.1080/19390210903070772.
    1. Scorei RI, Rotaru P. Calcium fructoborate—potential anti-inflammatory agent. Biol Trace Elem Res. 2011
    1. Scorei R, Cimpoiasu VM, Iordachescu D. In vitro evaluation of the antioxidant activity of calcium fructoborate. Biol Trace Elem Res. 2005;107:127–134. doi: 10.1385/BTER:107:2:127.
    1. Scorei R, Ciubar R, Iancu C, Mitran V, Cimpean A, Iordachescu D. In vitro effects of calcium fructoborate on fMLP stimulated human neutrophil granulocytes. Biol Trace Elem Res. 2007;118:27–37. doi: 10.1007/s12011-007-0019-7.
    1. Scorei RI, Ciofrangeanu C, Ion R, et al. In vitro effects of calcium fructoborate upon production of inflammatory mediators by LPS-stimulated RAW 264.7 macrophages. Biol Trace Elem Res. 2010;135:334–344. doi: 10.1007/s12011-009-8488-5.
    1. Kayne SB (ed) (2009) Complementary and alternative medicine, 2nd edn. Pharmaceutical Press, London
    1. Rotaru P, Scorei R, Harabor A, Dumitru MD. Thermal analysis of a calcium fructoborate sample. Thermochim Acta. 2010;506:8–13. doi: 10.1016/j.tca.2010.04.006.
    1. Vlad M, Zapirtan H, Creteanu E. Nutritional status in adult population in relation to the food intake. Romania: Annual Report of IPH Cluj-Napoca; 2003.
    1. Vlad M, Zapirtan H, Creteanu E. Food Intake and nutritional status of the population. annual national syntheses. Romania: Institute of Public Health Cluj-Napoca; 2008.
    1. Lee DH, Hong SH, Song J, Min W-K, Kim JQ. Fibrinogen gene polymorphism in a non-caucasian population. Clin Biochem. 1999;32:113–117. doi: 10.1016/S0009-9120(98)00095-2.
    1. Flood J, Liedtke R, Mattenheimer H, Rothouse L, Trundle D, Vroon D, Whisler K, Collinsworth W. A multicenter evaluation of the Boehringer Mannheim Hitachi 717 system. Clin Biochem. 1990;23:477–488. doi: 10.1016/0009-9120(90)80036-I.
    1. Sarban S, Kocyigit A, Yazar M, Isikan UE. Plasma total antioxidant capacity, lipid peroxidation, and erythrocyte antioxidant enzyme activities in patients with rheumatoid arthritis and osteoarthritis. Clin Biochem. 2005;38:981–986. doi: 10.1016/j.clinbiochem.2005.08.003.
    1. Hemker HC, Kop J, Willems GM. Kinetic aspects of the interaction of blood clotting enzymes, VII: the relation between clotting time and clotting velocity. Thromb Haemost. 1979;41:309–313.
    1. Sharif M, Shepstone L, Elson CJ, Dieppe PA, Kirwan JR. Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis. 2000;59:71–74. doi: 10.1136/ard.59.1.71.
    1. Spector TD, Hart DJ, Nandra D, Doyle, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum. 2005;40(4):723–727. doi: 10.1002/art.1780400419.
    1. Scorei RI, Popa R. Boron-containing compounds as preventive and chemotherapeutic agents for cancer. Anticancer Agents Med Chem. 2010;10(4):346–351. doi: 10.2174/187152010791162289.
    1. Scorei RI. Calcium fructoborate: plant-based dietary boron as potential medicine for cancer therapy. Front Biosci. 2011;S3(1):205–215. doi: 10.2741/s145.
    1. Manda D, Popa O, Vladoiu S, Dumitrache C. Calcium fructoborate effect on osteoblast mineralization in vitro. Bone. 2009;44(2):S298–S299. doi: 10.1016/j.bone.2009.03.545.
    1. World Health Organization (2010) International clinical trials registry platform search portal. Identifier ISRCTN02337806. Effects of resveratrol combined with calcium fructoborate (Fruitex B) in patients with stable angina pectoris. A 60 days double-blind-controlled pilot study. World Health Organization, Geneva. Available at:

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj